BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22927839)

  • 1. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma.
    Bijelic L; Stuart OA; Sugarbaker P
    Gastroenterol Res Pract; 2012; 2012():890450. PubMed ID: 22927839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
    Sugarbaker PH; Chang D
    Eur J Surg Oncol; 2017 Jul; 43(7):1228-1235. PubMed ID: 28189456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
    Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
    Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
    Huang Y; Alzahrani NA; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
    Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
    Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma.
    Sugarbaker PH
    Int J Surg Protoc; 2023 Dec; 27(3):108-117. PubMed ID: 38046900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 10. Peritoneal mesothelioma in Sweden: A population-based study.
    Cashin PH; Jansson Palmer G; Asplund D; Graf W; Syk I
    Cancer Med; 2019 Oct; 8(14):6468-6475. PubMed ID: 31483564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneal Mesothelioma: Systematic Review of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Protocol Outcomes.
    Kepenekian V; Sgarbura O; Marchal F; Villeneuve L; Glehen O; Kusamura S; Deraco M
    Indian J Surg Oncol; 2023 Jun; 14(Suppl 1):39-59. PubMed ID: 37359920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
    Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
    Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation.
    Peitl M; Seiwerth S; Bašić-Koretić M; Šantek F
    Indian J Med Paediatr Oncol; 2017; 38(1):73-77. PubMed ID: 28469343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
    de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
    BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesothelioma in children and adolescents: the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) contribution.
    Orbach D; André N; Brecht IB; López Almaraz R; Ben-Ami T; Vermersch S; Carton M; Virgone C; Bisogno G; Schneider DT; Bajciova V; Reguerre Y; Galateau-Salle F; Stachowicz-Stencel T; Dvir R; Rees H; Bien E; Ferrari A; Ben Arush M
    Eur J Cancer; 2020 Nov; 140():63-70. PubMed ID: 33049597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma.
    Kusamura S; Baratti D; De Simone M; Pasqual EM; Ansaloni L; Marrelli D; Robella M; Accarpio F; Valle M; Scaringi S; Biacchi D; Palopoli C; Gazzanelli S; Guaglio M; Deraco M
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diffuse malignant peritoneal mesothelioma (DMPM) - a rare diagnosis].
    Habbel VSA; Mahler EA; Feyerabend B; Oldhafer KJ; Lipp MJ
    Z Gastroenterol; 2020 Feb; 58(2):146-151. PubMed ID: 32050285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicystic and diffuse malignant peritoneal mesothelioma in children.
    Vermersch S; Arnaud A; Orbach D; Andre N; Berger C; Kepenekian V; Brigand C; Fresneau B; Poli-Merol ML; Habougit C; Varlet F; Scalabre A
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28286. PubMed ID: 32277799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
    Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
    Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.